ANV-700 / Anaveon - LARVOL DELTA

ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells (SITC 2024) - "Ethics Approval All animal experiments carried out at Anaveon were approved by the Cantonal Veterinary Office of Basel, Switzerland, and performed in accordance with the Swiss laws for animal welfare and protection and the 'Ethical Principles and Guidelines for Experiments on Animals by the Swiss Academies of Arts and Sciences'. The animal studies performed by Wuxi Biologics or CrownBio were approved by the respective Institutional Animal Care and Use Committees (IACUC)."

IO biomarker • Oncology • CD4 • CD8 • GZMB • IL21 • PD-1 • PRF1